Compositions of protein receptor tyrosine kinase inhibitors
US8809530B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 18, 2014 |
| Grant date | Aug 19, 2014 |
| Priority date | — |
| Expiry date | Apr 18, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF recptor TrkA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.